Provided by Tiger Trade Technology Pte. Ltd.

Editas Medicine

2.44
-0.1000-3.94%
Post-market: 2.460.0200+0.82%19:39 EDT
Volume:1.22M
Turnover:3.04M
Market Cap:238.19M
PE:-1.35
High:2.64
Open:2.60
Low:2.42
Close:2.54
52wk High:4.54
52wk Low:0.9101
Shares:97.62M
Float Shares:89.58M
Volume Ratio:0.40
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8036
EPS(LYR):-1.8036
ROE:-198.14%
ROA:-23.51%
PB:8.73
PE(LYR):-1.35

Loading ...

Editas Medicine price target lowered to $3.50 from $12 at Chardan

TIPRANKS
·
Nov 13, 2025

Cautious Hold Rating on Editas Medicine Amid Promising Preclinical Results and Development Uncertainties

TIPRANKS
·
Nov 12, 2025

Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Guardian Pharmacy Services, Inc. Class A (GRDN)

TIPRANKS
·
Nov 11, 2025

Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)

TIPRANKS
·
Nov 11, 2025

Editas Medicine Reports Q3 2025 Progress and Financials

TIPRANKS
·
Nov 11, 2025

Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate

Benzinga
·
Nov 10, 2025

Editas Medicine Q3 net loss narrows, beats expectations

Reuters
·
Nov 10, 2025

Editas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials

Reuters
·
Nov 10, 2025

BRIEF-Editas Medicine Q3 Net Income USD -25.117 Million Vs. IBES Estimate USD -28.1 Million

Reuters
·
Nov 10, 2025

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

THOMSON REUTERS
·
Nov 10, 2025

Editas Medicine Inc: on Track to Submit Ind/Cta for Edit-401 by Mid-2026, Achieve Initial Human Proof-of-Concept Data by Year-End 2026

THOMSON REUTERS
·
Nov 10, 2025

Editas Medicine Q3 Operating Income USD -24.548 Million

THOMSON REUTERS
·
Nov 10, 2025

Editas Medicine Q3 Net Income USD -25.117 Million VS. Ibes Estimate USD -28.1 Million

THOMSON REUTERS
·
Nov 10, 2025

Press Release: ONE Gas Announces Third Quarter 2025 Financial Results; Narrows 2025 Financial Guidance

Dow Jones
·
Nov 04, 2025

Editas Medicine Unveils Promising In Vivo CRISPR Cholesterol Therapy at AHA 2025

Reuters
·
Nov 03, 2025

Editas Medicine Inc expected to post a loss of 30 cents a share - Earnings Preview

Reuters
·
Oct 31, 2025

Editas Medicine’s Long-Term Study on EDIT-301: A Potential Game-Changer for Hemoglobinopathies

TIPRANKS
·
Oct 28, 2025

Editas Medicine management to meet with Cantor

TIPRANKS
·
Oct 24, 2025

H.C. Wainwright Sticks to Its Buy Rating for Editas Medicine (EDIT)

TIPRANKS
·
Oct 22, 2025

Editas Medicine reports in vivo preclinical PoC data for EDIT-401

TIPRANKS
·
Oct 09, 2025